Tumor profiling: Development of prognostic and predictive factors to guide brain tumor treatment

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 26-36

  Settle, Stephen H ^a   Sulman, Erik P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; Brain tumors; Copy number variation; DNA methylation; Ependymoma; Genomic profiling; Glioblastoma; Glioma; Medulloblastoma; Meningioma; Microarray; Predictive makers; Prognostic markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; EPENDYMOMA; GENE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SCREENING; HUMAN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 2 GENE; ISOCITRATE DEHYDROGENASE 1 GENE; MEDULLOBLASTOMA; MENINGIOMA; MICROARRAY ANALYSIS; MOLECULAR GENETICS; NEUROFIBROMATOSIS 2 GENE; NONHUMAN; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHOSPHATE AND TENSIN HOMOLOG GENE; PREDICTION; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CLASSIFICATION; TUMOR GROWTH;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; HUMAN GENOME PROJECT; HUMANS; MOLECULAR BIOLOGY; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551572433     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0138-8     Document Type: Article

References (91)

1. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
2. M Schena D Shalon RW Davis PO Brown 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray Science 270 5235 467 470 1:CAS:528:DyaK2MXovVersLk%3D 10.1126/science.270.5235.467 7569999
3. T Bammler RP Beyer S Bhattacharya, et al. 2005 Standardizing global gene expression analysis between laboratories and across platforms Nat Methods 2 5 351 356 10.1038/nmeth754 15846362 (Pubitemid 41130980)
4. AC Pease D Solas EJ Sullivan, et al. 1994 Light-generated oligonucleotide arrays for rapid DNA sequence analysis Proc Natl Acad Sci U S A 91 11 5022 5026 1:CAS:528:DyaK2cXltVSktrc%3D 10.1073/pnas.91.11.5022 8197176 (Pubitemid 24177783)
5. MB Eisen PT Spellman PO Brown D Botstein 1998 Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci U S A 95 25 14863 14868 1:CAS:528:DyaK1cXotVGmurk%3D 10.1073/pnas.95.25.14863 9843981 (Pubitemid 29003722)
6. DB Allison X Cui GP Page M Sabripour 2006 Microarray data analysis: from disarray to consolidation and consensus Nat Rev Genet 7 1 55 65 1:CAS:528:DC%2BD2MXhtlanu73F 10.1038/nrg1749 16369572 (Pubitemid 41828948)
7. AA Alizadeh MB Eisen RE Davis, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 6769 503 511 1:CAS:528:DC%2BD3cXht1Shtrg%3D 10.1038/35000501 10676951 (Pubitemid 30082188)
8. J Baker 2007 Genomic Health, Inc Pharmacogenomics 8 4 397 399 1:STN:280:DC%2BD2s7ptVajsw%3D%3D 10.2217/14622416.8.4.397 17391076 (Pubitemid 46585500)
9. AM Glas A Floore LJ Delahaye, et al. 2006 Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 278 10.1186/1471-2164-7-278 17074082 (Pubitemid 44773844)
10. ER Mardis 2008 The impact of next-generation sequencing technology on genetics Trends Genet 24 3 133 141 1:CAS:528:DC%2BD1cXislKht74%3D 18262675
11. ER Mardis 2008 Next-generation DNA sequencing methods Annu Rev Genomics Hum Genet 9 387 402 1:CAS:528:DC%2BD1cXht1SnsbbJ 10.1146/annurev.genom.9.081307. 164359 18576944
12. R Chari BP Coe C Wedseltoft, et al. 2008 SIGMA2: a system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes BMC Bioinformatics 9 422 10.1186/1471-2105-9-422 18840289
13. GN Fuller CH Rhee KR Hess, et al. 1999 Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling Cancer Res 59 17 4228 4232 1:CAS:528:DyaK1MXlvVSmsr8%3D 10485462
14. LS Caskey GN Fuller JM Bruner, et al. 2000 Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling Histol Histopathol 15 3 971 981 1:CAS:528: DC%2BD3cXmsFOmtLg%3D 10963139
15. H Huang S Colella M Kurrer, et al. 2000 Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays Cancer Res 60 24 6868 6874 1:CAS:528:DC%2BD3MXjsVKqsQ%3D%3D 11156382
16. SL Sallinen PK Sallinen HK Haapasalo, et al. 2000 Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques Cancer Res 60 23 6617 6622 1:CAS:528:DC%2BD3cXosl2isbg%3D 11118044
17. A Chakravarti MA Delaney E Noll, et al. 2001 Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas Clin Cancer Res 7 8 2387 2395 1:CAS:528:DC%2BD3MXmsVOmtL4%3D 11489817
18. K Somasundaram SP Reddy K Vinnakota, et al. 2005 Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma Oncogene 24 47 7073 7083 1:CAS:528:DC%2BD2MXhtFCru7%2FP 10.1038/sj.onc.1208865 16103883 (Pubitemid 41573636)
19. SM Raza GN Fuller CH Rhee, et al. 2004 Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis Clin Cancer Res 10 1 Pt 1 212 221 1:CAS:528:DC%2BD2cXkvF2mtw%3D%3D 10.1158/1078-0432.CCR-0155-3 14734472 (Pubitemid 38114182)
20. LH Carvalho I Smirnov GS Baia, et al. 2007 Molecular signatures define two main classes of meningiomas Mol Cancer 6 64 10.1186/1476-4598-6-64 17937814
21. M Aarhus O Bruland G Bredholt, et al. 2008 Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas J Neurooncol 88 3 251 259 1:CAS:528:DC%2BD1cXosFKju7k%3D 10.1007/s11060-008-9569-6 18365142
22. S Goutagny HW Yang J Zucman-Rossi, et al. 2010 Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status Clin Cancer Res 16 16 4155 4164 1:CAS:528: DC%2BC3cXhtVajs73J 10.1158/1078-0432.CCR-10-0891 20682713
23. TJ MacDonald KM Brown B LaFleur, et al. 2001 Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease Nat Genet 29 2 143 152 1:CAS:528:DC%2BD3MXnsFKgtb0%3D 10.1038/ng731 11544480 (Pubitemid 32952650)
24. SL Pomeroy P Tamayo M Gaasenbeek, et al. 2002 Prediction of central nervous system embryonal tumour outcome based on gene expression Nature 415 6870 436 442 1:CAS:528:DC%2BD38XhtVCqtr0%3D 10.1038/415436a 11807556 (Pubitemid 34100955)
25. PC Park MD Taylor TG Mainprize, et al. 2003 Transcriptional profiling of medulloblastoma in children J Neurosurg 99 3 534 541 10.3171/jns.2003.99.3.0534 12959442
26. K Neben A Korshunov A Benner, et al. 2004 Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival Cancer Res 64 9 3103 3111 1:CAS:528:DC%2BD2cXjs1ehtrs%3D 10.1158/0008-5472.CAN-03-3968 15126347 (Pubitemid 38581410)
27. MC Thompson C Fuller TL Hogg, et al. 2006 Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations J Clin Oncol 24 12 1924 1931 1:CAS:528:DC%2BD28XkvVajtbY%3D 10.1200/JCO.2005.04. 4974 16567768 (Pubitemid 46638992)
28. A Korshunov K Neben G Wrobel, et al. 2003 Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age Am J Pathol 163 5 1721 1727 1:CAS:528:DC%2BD3sXpsVWlt70%3D 14578171
29. CC Lau 2005 Genomic profiling in pediatric brain tumors Cancer J 11 4 283 293 1:CAS:528:DC%2BD2MXhtFegtLvK 10.1097/00130404-200507000-00004 16197718
30. B Suarez-Merino M Hubank T Revesz, et al. 2005 Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 Neuro Oncol 7 1 20 31 1:CAS:528: DC%2BD2MXhvFyrsbY%3D 10.1215/S1152851704000596 15701279 (Pubitemid 40310190)
31. MD Taylor H Poppleton C Fuller, et al. 2005 Radial glia cells are candidate stem cells of ependymoma Cancer Cell 8 4 323 335 1:CAS:528: DC%2BD2MXhtFOrtLvN 10.1016/j.ccr.2005.09.001 16226707 (Pubitemid 41443417)
32. RJ Gilbertson 2006 Brain tumors provide new clues to the source of cancer stem cells: does oncology recapitulate ontogeny? Cell Cycle 5 2 135 137 1:CAS:528:DC%2BD28XisVantLw%3D 10.4161/cc.5.2.2319 16357533
33. P Modena E Lualdi F Facchinetti, et al. 2006 Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics J Clin Oncol 24 33 5223 5233 1:CAS:528: DC%2BD28XhtlemurbP 10.1200/JCO.2006.06.3701 17114655 (Pubitemid 46631366)
34. K Sowar J Straessle AM Donson, et al. 2006 Predicting which children are at risk for ependymoma relapse J Neurooncol 78 1 41 46 10.1007/s11060-005-9072-2 16575538 (Pubitemid 43786656)
35. I Lukashova-v Zangen S Kneitz CM Monoranu, et al. 2007 Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival Acta Neuropathol 113 3 325 337 10.1007/s00401-006-0190-5 17265049 (Pubitemid 46443567)
36. JM de Bont JM Kros MM Passier, et al. 2008 Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis Neuro Oncol 10 5 648 660 10.1215/15228517- 2008-032 18577562
37. RA Johnson KD Wright H Poppleton, et al. 2010 Cross-species genomics matches driver mutations and cell compartments to model ependymoma Nature 466 7306 632 636 1:CAS:528:DC%2BC3cXovFCgu7k%3D 10.1038/nature09173 20639864
38. DS Rickman MP Bobek DE Misek, et al. 2001 Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis Cancer Res 61 18 6885 6891 1:CAS:528:DC%2BD3MXntFaitrw%3D 11559565
39. B Dai SH Kang W Gong, et al. 2007 Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells Oncogene 26 42 6212 6219 1:CAS:528:DC%2BD2sXhtVeisLjN 10.1038/sj.onc. 1210443 17404569 (Pubitemid 47414378)
40. M Liu B Dai SH Kang, et al. 2006 FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells Cancer Res 66 7 3593 3602 1:CAS:528:DC%2BD28XjtVOrsL4%3D 10.1158/0008-5472.CAN-05-2912 16585184
41. MT Teh ST Wong GW Neill, et al. 2002 FOXM1 is a downstream target of Gli1 in basal cell carcinomas Cancer Res 62 16 4773 4780 1:CAS:528: DC%2BD38XmsVShsbk%3D 12183437
42. HC Cheung KA Baggerly S Tsavachidis, et al. 2008 Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays BMC Genomics 9 216 10.1186/1471-2164-9-216 18474104 (Pubitemid 351785140)
43. PJ French J Peeters S Horsman, et al. 2007 Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays Cancer Res 67 12 5635 5642 1:CAS:528: DC%2BD2sXmsFCqs7c%3D 10.1158/0008-5472.CAN-06-2869 17575129 (Pubitemid 46984994)
44. MK Tanwar MR Gilbert EC Holland 2002 Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma Cancer Res 62 15 4364 4368 1:CAS:528:DC%2BD38XlvFelurs%3D 12154041
45. S Khatua KM Peterson KM Brown, et al. 2003 Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling Cancer Res 63 8 1865 1870 1:CAS:528: DC%2BD3sXivFynsL8%3D 12702575
46. Y Liang M Diehn N Watson, et al. 2005 Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme Proc Natl Acad Sci U S A 102 16 5814 5819 1:CAS:528:DC%2BD2MXjslaktb0%3D 10.1073/pnas.0402870102 15827123 (Pubitemid 40559642)
47. JM Nigro A Misra L Zhang, et al. 2005 Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma Cancer Res 65 5 1678 1686 1:CAS:528:DC%2BD2MXitVOjs7c%3D 10.1158/0008-5472.CAN-04-2921 15753362 (Pubitemid 40478592)
48. F Liu PJ Park W Lai, et al. 2006 A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma Cancer Res 66 22 10815 10823 1:CAS:528:DC%2BD2sXivVyqsb8%3D 10.1158/0008-5472.CAN-06-1408 17090523 (Pubitemid 44876977)
49. D Faury A Nantel SE Dunn, et al. 2007 Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors J Clin Oncol 25 10 1196 1208 1:CAS:528:DC%2BD2sXkvFymsrY%3D 10.1200/JCO.2006.07.8626 17401009 (Pubitemid 46640565)
50. KL McDonald MG O'Sullivan JF Parkinson, et al. 2007 IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients J Neuropathol Exp Neurol 66 5 405 417 1:CAS:528:DC%2BD2sXmtVyqtr8%3D 10.1097/nen. 0b013e31804567d7 17483698 (Pubitemid 46701323)
51. SP Reddy R Britto K Vinnakota, et al. 2008 Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis Clin Cancer Res 14 10 2978 2987 1:CAS:528:DC%2BD1cXmtVCmtLo%3D 10.1158/1078-0432.CCR-07-4821 18483363
52. Y Ruano M Mollejo FI Camacho, et al. 2008 Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme Cancer 112 7 1575 1584 1:CAS:528: DC%2BD1cXktlKrurg%3D 10.1002/cncr.23338 18260157 (Pubitemid 351441171)
53. CA Scrideli CG Carlotti Jr 2008 Okamoto OK, et al. Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR J Neurooncol 88 3 281 291 1:CAS:528: DC%2BD1cXosFKisr4%3D 10.1007/s11060-008-9579-4 18398573
54. CL Nutt RA Betensky MA Brower, et al. 2005 YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas Clin Cancer Res 11 6 2258 2264 1:CAS:528:DC%2BD2MXisFaju7w%3D 10.1158/1078-0432.CCR-04-1601 15788675 (Pubitemid 40490185)
55. CE Pelloski A Mahajan M Maor, et al. 2005 YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma Clin Cancer Res 11 9 3326 3334 1:CAS:528:DC%2BD2MXjslOqtrg%3D 10.1158/1078-0432.CCR-04-1765 15867231 (Pubitemid 40627883)
56. CE Pelloski E Lin L Zhang, et al. 2006 Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma Clin Cancer Res 12 13 3935 3941 1:CAS:528:DC%2BD28XmsValtLs%3D 10.1158/1078-0432. CCR-05-2202 16818690 (Pubitemid 44078078)
57. O Persson M Krogh LH Saal, et al. 2007 Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets J Neurooncol 85 1 11 24 1:CAS:528: DC%2BD2sXht1amsL7I 10.1007/s11060-007-9383-6 17634744 (Pubitemid 47422652)
58. O Bozinov S Kohler B Samans, et al. 2008 Candidate genes for the progression of malignant gliomas identified by microarray analysis Neurosurg Rev 31 1 83 89 10.1007/s10143-007-0107-3 17917751 discussion 89-90 (Pubitemid 350165337)
59. T Czernicki J Zegarska L Paczek, et al. 2007 Gene expression profile as a prognostic factor in high-grade gliomas Int J Oncol 30 1 55 64 1:CAS:528:DC%2BD2sXhtFyrtL4%3D 17143512
60. S Godard G Getz M Delorenzi, et al. 2003 Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes Cancer Res 63 20 6613 6625 1:CAS:528:DC%2BD3sXosVGgurw%3D 14583454
61. S Kim ER Dougherty I Shmulevich, et al. 2002 Identification of combination gene sets for glioma classification Mol Cancer Ther 1 13 1229 1236 1:CAS:528:DC%2BD3sXmvFOgtw%3D%3D 12479704
62. J Margareto O Leis E Larrarte, et al. 2007 Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways J Mol Neurosci 32 1 53 63 1:CAS:528:DC%2BD2sXos1Giu7o%3D 10.1007/s12031-007-0008-5 17873288 (Pubitemid 47450557)
63. CL Nutt DR Mani RA Betensky, et al. 2003 Gene expression-based classification of malignant gliomas correlates better with survival than histological classification Cancer Res 63 7 1602 1607 1:CAS:528: DC%2BD3sXisFaitbc%3D 12670911
64. R Shai T Shi TJ Kremen, et al. 2003 Gene expression profiling identifies molecular subtypes of gliomas Oncogene 22 31 4918 4923 1:CAS:528: DC%2BD3sXlvVKnsrY%3D 10.1038/sj.onc.1206753 12894235 (Pubitemid 36981282)
65. J van den Boom M Wolter R Kuick, et al. 2003 Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction Am J Pathol 163 3 1033 1043 12937144
66. HS Phillips S Kharbanda R Chen, et al. 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 3 157 173 1:CAS:528:DC%2BD28XivFWjtL4%3D 10.1016/j.ccr.2006.02.019 16530701 This article identified the proneural, mesenchymal, and proliferative molecular signatures in high-grade gliomas, which have subsequently been recapitulated in multiple datasets (Pubitemid 43357943)
67. LA Gravendeel MC Kouwenhoven O Gevaert, et al. 2009 Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res 69 23 9065 9072 1:CAS:528:DC%2BD1MXhsV2itLnO 10.1158/0008-5472.CAN- 09-2307 19920198
68. H Colman L Zhang EP Sulman, et al. 2010 A multigene predictor of outcome in glioblastoma Neuro Oncol 12 1 49 57 1:CAS:528:DC%2BC3cXjvFCnt7c%3D 20150367 These authors developed the first multigene prognostic clinical test in GBM based on gene expression profiling
69. MA Watson A Perry V Budhraja, et al. 2001 Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas Cancer Res 61 5 1825 1829 1:CAS:528:DC%2BD3MXit1Ohurg%3D 11280731
70. A Mukasa K Ueki S Matsumoto, et al. 2002 Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p Oncogene 21 25 3961 3968 1:CAS:528:DC%2BD38XkslWqt7Y%3D 10.1038/sj.onc.1205495 12037678 (Pubitemid 34679237)
71. H Huang Y Okamoto H Yokoo, et al. 2004 Gene expression profiling and subgroup identification of oligodendrogliomas Oncogene 23 35 6012 6022 1:CAS:528:DC%2BD2cXmt1Krtrk%3D 10.1038/sj.onc.1207781 15208679 (Pubitemid 39093547)
72. A Mukasa K Ueki X Ge, et al. 2004 Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss Brain Pathol 14 1 34 42 1:CAS:528:DC%2BD2cXhvVKiu7c%3D 10.1111/j.1750-3639.2004.tb00495.x 14997935
73. PJ French SM Swagemakers JH Nagel, et al. 2005 Gene expression profiles associated with treatment response in oligodendrogliomas Cancer Res 65 24 11335 11344 1:CAS:528:DC%2BD2MXhtlWiu7%2FO 10.1158/0008-5472.CAN-05-1886 16357140 (Pubitemid 41821690)
74. B Tews J Felsberg C Hartmann, et al. 2006 Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling Int J Cancer 119 4 792 800 1:CAS:528:DC%2BD28XntVeqtrc%3D 10.1002/ijc.21901 16550607 (Pubitemid 44051441)
75. F Ducray A Idbaih A de Reynies, et al. 2008 Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile Mol Cancer 7 41 10.1186/1476-4598-7-41 18492260 (Pubitemid 351816762)
76. D Hagerstrand A Smits A Eriksson, et al. 2008 Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker Neuro Oncol 10 1 2 9 10.1215/15228517-2007-041 18003890 (Pubitemid 351250895)
77. JG Cairncross K Ueki MC Zlatescu, et al. 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 19 1473 1479 1:STN:280: DyaK1cvkslejug%3D%3D 10.1093/jnci/90.19.1473 9776413
78. DW Parsons S Jones X Zhang, et al. 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 5897 1807 1812 1:CAS:528: DC%2BD1cXhtFCrtLrE 10.1126/science.1164382 18772396 A whole exome (all expressed genes) sequence analysis of GBM identified a previously unknown mutation of the IDH1 gene with important prognostic significance in gliomas
79. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
80. RG Verhaak KA Hoadley E Purdom, et al. 2010 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 1 98 110 1:CAS:528:DC%2BC3cXkvFKgsL4%3D 10.1016/j.ccr.2009.12.020 20129251
81. H Yan DW Parsons G Jin, et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 8 765 773 1:CAS:528:DC%2BD1MXitFWru7o%3D 10.1056/NEJMoa0808710 19228619
82. S Nobusawa T Watanabe P Kleihues H Ohgaki 2009 IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 19 6002 6007 1:CAS:528:DC%2BD1MXhtF2ltbbL 10.1158/1078-0432.CCR-09-0715 19755387
83. C Brennan H Momota D Hambardzumyan, et al. 2009 Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations PLoS One 4 11 e7752 10.1371/journal.pone.0007752 19915670
84. H Noushmehr DJ Weisenberger K Diefes, et al. 2010 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 5 510 522 1:CAS:528:DC%2BC3cXmslKqsr0%3D 10.1016/j.ccr.2010.03.017 20399149 This article used publically available DNA promotor methylation data to identify an epigenetic signature, G-CIMP, as a novel prognostic biomarker in gliomas
85. S Paik S Shak G Tang, et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2817 2826 1:CAS:528:DC%2BD2MXhslymsw%3D%3D 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)
86. MJ van de Vijver YD He LJ van't Veer, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
87. M Esteller J Garcia-Foncillas E Andion, et al. 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 19 1350 1354 1:CAS:528:DC%2BD3cXosFOltLg%3D 10.1056/ NEJM200011093431901 11070098
88. ME Hegi AC Diserens T Gorlia, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
89. R Stupp ME Hegi WP Mason, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 5 459 466 1:CAS:528:DC%2BD1MXlsVKhs74%3D 10.1016/S1470-2045(09)70025-7 19269895
90. AL Rivera CE Pelloski MR Gilbert, et al. 2010 MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 2 116 121 1:CAS:528:DC%2BC3cXotFKitb8%3D 20150378
91. Sulman EP, Guerrero M, Aldape K: Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification. In: CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches. Edited by Van Meir EG. New YOrk: Humana Press; 2009: 529-552.